This study demonstrated that compared with low SLC2A1, high SLC2A1 was related to worse clinical outcomes, such as advanced T and N stage, large tumor size, lymphatic invasion, mutation, copy number gain/amplification and hypomethylation in patients with gastric cancer. The gene discussed is SLC2A1; the disease is neoplasm.